标题
Emerging immunotherapy for HCC: A guide for hepatologists
作者
关键词
-
出版物
HEPATOLOGY
Volume 75, Issue 6, Pages 1604-1626
出版商
Wiley
发表日期
2022-03-07
DOI
10.1002/hep.32447
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
- (2022) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
- (2022) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma.
- (2022) Friedrich Foerster et al. JOURNAL OF CLINICAL ONCOLOGY
- TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization combined with atezolizumab + bevacizumab or on-demand transarterial chemoembolization alone in patients with untreated hepatocellular carcinoma.
- (2022) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).
- (2021) Bruno Sangro et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Disease Primers
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- (2021) Dominik Pfister et al. NATURE
- P-61 Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073
- (2021) B. Sangro et al. ANNALS OF ONCOLOGY
- Phase I trial of fourth-generation chimeric antigen receptor T-cells targeting glypican-3 for advanced hepatocellular carcinoma.
- (2021) Weijia Fang et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
- (2021) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
- (2021) Zhenggang Ren et al. LANCET ONCOLOGY
- Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
- (2020) Stephen P Hack et al. Future Oncology
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- P-347 A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma: EMERALD-1
- (2020) B. Sangro et al. ANNALS OF ONCOLOGY
- Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design
- (2020) Robin Kate Kelley et al. Future Oncology
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- 1016TiP LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
- (2020) J.M. Llovet et al. ANNALS OF ONCOLOGY
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma
- (2020) Yunfan Sun et al. CELL
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome
- (2019) Jing Liu et al. OncoImmunology
- Abstract No. 526 CheckMate-9DX: phase 3, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation
- (2019) M. Jimenez Exposito et al. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
- Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells
- (2019) Ming Zhong et al. BMC CANCER
- RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
- (2019) Shukui Qin et al. Future Oncology
- Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
- (2019) Josep M Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
- (2019) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- P-217A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2
- (2019) J Knox et al. ANNALS OF ONCOLOGY
- Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma
- (2019) Lynn G. Feun et al. CANCER
- Tumour-associated neutrophils in patients with cancer
- (2019) Merav E. Shaul et al. Nature Reviews Clinical Oncology
- β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
- (2019) Marina Ruiz de Galarreta et al. Cancer Discovery
- Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
- (2019) M. Moehler et al. OncoImmunology
- Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
- (2019) Audrey Simonaggio et al. JAMA Oncology
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer
- (2019) Lichun Ma et al. CANCER CELL
- Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma
- (2019) Qiming Zhang et al. CELL
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
- (2018) Chris Estes et al. JOURNAL OF HEPATOLOGY
- Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations
- (2018) Jean-Charles Nault et al. JOURNAL OF HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EG FR -Mutant Lung Adenocarcinoma
- (2018) Po-Hao Feng et al. Journal of Thoracic Oncology
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
- (2018) Chi Ma et al. SCIENCE
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
- (2018) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma
- (2018) Su Jong Yu et al. JOURNAL OF HEPATOLOGY
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
- (2017) Daniela Sia et al. GASTROENTEROLOGY
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
- (2017) Wei Jia et al. Nature Reviews Gastroenterology & Hepatology
- Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
- (2017) Priti S. Hegde et al. SEMINARS IN CANCER BIOLOGY
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
- (2017) Peng-Fei Wang et al. Frontiers in Pharmacology
- Liver-infiltrating CD11b−CD27− NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression
- (2016) Qiong-Fang Zhang et al. Cellular & Molecular Immunology
- Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib
- (2016) Shao-Lai Zhou et al. GASTROENTEROLOGY
- Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data
- (2016) Riccardo Lencioni et al. HEPATOLOGY
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
- (2016) J. Liu et al. Cancer Discovery
- PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression
- (2016) X. Xiao et al. Cancer Discovery
- TGF-β induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype
- (2016) Fan Zhang et al. Oncotarget
- Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
- (2016) A. Gabrielson et al. Cancer Immunology Research
- Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments
- (2016) Elisabetta Cariani et al. OncoImmunology
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- TGF-β Regulates Hepatocellular Carcinoma Progression by Inducing Treg Cell Polarization
- (2015) Yinan Shen et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- High Serum Transforming Growth Factor- 1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib
- (2015) T.-H. Lin et al. CLINICAL CANCER RESEARCH
- Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma
- (2015) Marta Garnelo et al. GUT
- Chemokine (C-X-C motif) receptor 3-positive B cells link interleukin-17 inflammation to protumorigenic macrophage polarization in human hepatocellular carcinoma
- (2015) Rui-Xian Liu et al. HEPATOLOGY
- Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma
- (2015) Oscar W.H. Yeung et al. JOURNAL OF HEPATOLOGY
- The yin and yang of evasion and immune activation in HCC
- (2015) Oxana V. Makarova-Rusher et al. JOURNAL OF HEPATOLOGY
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- (2015) Jordi Bruix et al. LANCET ONCOLOGY
- IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia
- (2015) Y. Pylayeva-Gupta et al. Cancer Discovery
- Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study
- (2014) D. J. Pinato et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
- (2014) M.-G. Anitei et al. CLINICAL CANCER RESEARCH
- Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance
- (2014) Agustín Albillos et al. JOURNAL OF HEPATOLOGY
- NK Cells Are the Crucial Antitumor Mediators When STAT3-Mediated Immunosuppression Is Blocked in Hepatocellular Carcinoma
- (2014) Qiangjun Sui et al. JOURNAL OF IMMUNOLOGY
- Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
- (2014) E. Horwitz et al. Cancer Discovery
- Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
- (2013) Fumitaka Arihara et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L
- (2013) M. Bodogai et al. CANCER RESEARCH
- Higher Frequencies of GARP+CTLA-4+Foxp3+ T Regulatory Cells and Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Are Associated with Impaired T-Cell Functionality
- (2013) S. Kalathil et al. CANCER RESEARCH
- HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virus-Related Hepatocellular Carcinoma
- (2013) E. Cariani et al. CLINICAL CANCER RESEARCH
- Human CD14+CTLA-4+regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma
- (2013) Yanmei Han et al. HEPATOLOGY
- Immunodominance and functional alterations of tumor-associated antigen-specific CD8+T-cell responses in hepatocellular carcinoma
- (2013) Tobias Flecken et al. HEPATOLOGY
- Immune surveillance by the liver
- (2013) Craig N Jenne et al. NATURE IMMUNOLOGY
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Increased Circulating Th17 Cells after Transarterial Chemoembolization Correlate with Improved Survival in Stage III Hepatocellular Carcinoma: A Prospective Study
- (2013) Yuan Liao et al. PLoS One
- Combination of Intratumoral Invariant Natural Killer T Cells and Interferon-Gamma Is Associated with Prognosis of Hepatocellular Carcinoma after Curative Resection
- (2013) Yong-Sheng Xiao et al. PLoS One
- Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
- (2012) Dianne H. Dapito et al. CANCER CELL
- Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma
- (2012) Shao-Lai Zhou et al. HEPATOLOGY
- Resection of hepatocellular cancer ≤2 cm: Results from two Western centers
- (2012) Sasan Roayaie et al. HEPATOLOGY
- Dendritic Cell-Based Vaccines Positively Impact Natural Killer and Regulatory T Cells in Hepatocellular Carcinoma Patients
- (2011) Sarah M. Bray et al. Clinical & Developmental Immunology
- Selective Recruitment of Regulatory T Cell through CCR6-CCL20 in Hepatocellular Carcinoma Fosters Tumor Progression and Predicts Poor Prognosis
- (2011) Kang-Jie Chen et al. PLoS One
- Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents
- (2010) Le-Xing Yu et al. HEPATOLOGY
- CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes
- (2010) B. H. Nelson JOURNAL OF IMMUNOLOGY
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor
- (2009) Bastian Hoechst et al. HEPATOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells
- (2008) Bastian Hoechst et al. GASTROENTEROLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started